Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
06.06. | TELA Bio, Inc.: TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 130 | GlobeNewswire (Europe) | MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
03.06. | TELA Bio, Inc.: TELA Bio Announces European Commercial Launch of OviTex Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair | 95 | GlobeNewswire (Europe) | MALVERN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today... ► Artikel lesen | |
02.06. | TELA Bio ernennt Jeffrey Blizard zum neuen Präsidenten | 2 | Investing.com Deutsch | ||
TELA BIO Aktie jetzt für 0€ handeln | |||||
02.06. | TELA Bio, Inc.: TELA Bio Appoints Jeffrey Blizard as President | 133 | GlobeNewswire (Europe) | MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today... ► Artikel lesen | |
30.05. | TELA Bio, Inc. - 8-K, Current Report | 6 | SEC Filings | ||
20.05. | Piper Sandler maintains TELA Bio stock at Neutral with $2 target | 2 | Investing.com | ||
09.05. | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 99 | GlobeNewswire (Europe) | MALVERN, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
09.05. | TELA Bio GAAP EPS of -$0.25 misses by $0.05, revenue of $18.5M beats by $1.15M | 2 | Seeking Alpha | ||
08.05. | TELA Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
17.04. | TELA Bio, Inc.: TELA Bio to Announce First Quarter 2025 Financial Results | 2 | GlobeNewswire (USA) | ||
09.04. | Canaccord maintains TELA Bio stock with $7 target post-challenges | 1 | Investing.com | ||
31.03. | TELA Bio introduces larger sizes for soft tissue reconstruction | 1 | Investing.com | ||
31.03. | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
31.03. | TELA Bio, Inc.: TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex PRS for Plastic and Reconstructive Surgery | 1 | GlobeNewswire (USA) | ||
22.03. | TELA Bio, Inc. (NASDAQ:TELA) Q4 2024 Earnings Call Transcript | 1 | Insider Monkey | ||
21.03. | TELA Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
21.03. | TELA Bio, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
21.03. | Tela Bio slumps after Q4 miss as Piper Sandler downgrades | 2 | Seeking Alpha | ||
21.03. | Canaccord cuts TELA Bio stock target to $7, maintains Buy | 3 | Investing.com | ||
21.03. | TELA Bio stock price target cut to $7 by Citizens JMP | 2 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MODERNA | 27,305 | -2,45 % | Tesla und Moderna: Das sind die Short-Kandidaten von JPMorgan | © Foto: DALL*ETesla und Moderna gehören zu den Aktien, bei denen JPMorgan im zweiten Halbjahr 2025 zu Short-Positionen rät.Zum Start ins zweite Halbjahr ließ Pedro Martins Junior, Co-Leiter der US-Aktienanalyse... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 12,080 | -0,29 % | Aktien New York: Weitere Gewinne nach guten Firmennachrichten | NEW YORK (dpa-AFX) - Die New Yorker Börsen haben am Donnerstag an ihre freundliche Vortagsentwicklung angeknüpft. Der Leitindex Dow Jones Industrial notierte zuletzt 0,44 Prozent höher bei 44.447,68... ► Artikel lesen | |
PACIFIC BIOSCIENCES OF CALIFORNIA | 1,189 | +1,21 % | PacBio Board Independent Investigation Concludes Allegations Unsubstantiated | MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the "Special Committee") has concluded its independent... ► Artikel lesen | |
PHIO PHARMACEUTICALS | 2,440 | +0,41 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort | -Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in fourth cohort, permitting dose escalation in expected final cohortMarlborough, Massachusetts--(Newsfile Corp. -... ► Artikel lesen | |
CYTOMX THERAPEUTICS | 2,106 | +2,63 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA (pembrolizumab) in Patients with Metastatic Melanoma | SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the... ► Artikel lesen | |
VIR BIOTECHNOLOGY | 5,415 | -1,46 % | Vir Biotechnology, Inc.: Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study | HBsAg loss 24 weeks post-end of treatment achieved in 17% and 21% of participants with low baseline HBsAg receiving tobevibart elebsiran without or with PEG-IFNa, respectively As previously... ► Artikel lesen | |
RAPT THERAPEUTICS | 9,660 | -3,98 % | XFRA 0RA0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
TC BIOPHARM | 0,825 | 0,00 % | TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient | First patient in Cohort B achieved CR after 2nd dose of TCB008
EDINBURGH, Scotland, June 11, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC (NASDAQ: TCBP)... ► Artikel lesen | |
QIAGEN | 41,405 | -0,35 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen | |
NUVALENT | 83,40 | -2,67 % | Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the... ► Artikel lesen | |
IMMUNOVANT | 17,910 | -2,02 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 | Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD)... ► Artikel lesen | |
EVOTEC | 7,456 | +0,59 % | Evotec-Aktie mit Kursgewinnen (7,346 €) | Im Plus liegt derzeit der Anteilsschein von Evotec . Das Papier kostete zuletzt 7,35 Euro. Heute hat sich am deutschen Aktienmarkt das Wertpapier von Evotec zwischenzeitlich um 3,41 Prozent verteuert.... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,845 | +5,89 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
SUMMIT THERAPEUTICS | 26,200 | -5,18 % | Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings | ||
BIONTECH | 94,40 | -2,13 % | DAX-Korrektur! BioTech Im Übernahme-Modus! BioNTech, CureVac, Pfizer, Vidac Pharma und Kraft Heinz im Fokus | Die Aktienmärkte zeigen sich in Bestform: Sowohl der DAX als auch der NASDAQ 100 haben in den vergangenen Tagen Muskeln gezeigt. Angetrieben werden die Kurse vor allem von der anhaltenden Stärke der... ► Artikel lesen |